JPRN-UMIN000004265已完成未知
evaluation of safety and efficacy of therapeutic angiogenesis by low-energy extracorporeal shock wave to peripheral arterial disease - evaluation of safety and efficacy of low-energy extracorporeal shock wave therapy
Department of Medicine (Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine)0 个研究点目标入组 20 人开始时间: 2010年9月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patients can not agree with this study
研究者
相似试验
进行中（未招募）
1 期
Evaluation of treatment effectiveness and safety of somatic cell based therapy for urinary incontinence in patients after radical prostatectomy.urinary incontinenceMedDRA version: 20.0Level: LLTClassification code: 10021643Term: Incontinence urinary Class: 10038359CTIS2023-509812-27-00icolaus Copernicus University45
招募中
2 期
Therapeutic effect of dalfampridine on patients with Devic syndromeDevic.Neuromyelitis optica [Devic]G36.0IRCT20210917052506N1Esfahan University of Medical Sciences70
已完成
4 期
Evaluation of the therapeutic efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated falciparum malaria in areas of artemisinin-resistant falciparum malaria in Viet NamACTRN12618001274268Ministry of Health, Viet Nam153
进行中（未招募）
1 期
Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)MedDRA version: 18.0Level: LLTClassification code 10048043Term: WrinklingSystem Organ Class: 100000004858EUCTR2014-001815-38-DEAllergan Limited750
进行中（未招募）
1 期
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown LinesFacial Rhytides (Forehead Lines, Glabellar Lines)MedDRA version: 18.1Level: LLTClassification code 10048043Term: WrinklingSystem Organ Class: 100000004858EUCTR2014-001860-36-IEAllergan Limited400